EULAR 2021: Expert Insights on Axial Spondyloarthritis and Axial Psoriatic Arthritis
  • CME

June 2-5, 2021; Virtual
Read these expert commentaries from Dr. Philip Mease and Dr. Athul Deodhar on how the latest data presented at EULAR 2021 will affect the clinical management of axial psoriatic arthritis and axial spondyloarthritis.
Atul Deodhar, MD
Philip Mease, MD, MACR
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: September 2, 2021 Expiration: September 1, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the latest information on use of clinical, imaging, and serologic testing for axSpA and axPsA and implications in diagnosis and monitoring
  • Summarize the findings of key studies of conventional and targeted therapies for axSpA and axPsA and the potential implications in treatment selection


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Philip Mease, MD, MACR

Clinical Professor
School of Medicine
University of Washington
Rheumatology Research
Swedish Medical Center
Providence St Joseph Health
Seattle, Washington

Philip Mease, MD, MACR, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; funds for research from AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and fees for non-CME/CE services from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB.
Atul Deodhar, MD
Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon
Atul Deodhar, MD, MRCP, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB; and funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB.


Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatology and primary care physicians, and other HCPs who care for patients with axial manifestations.


The goal of this educational program is to increase the knowledge and competence of learners in evaluating the latest data for axSpA and axPsA from EULAR 2021 and integrating the most clinically important data to clinical practice for appropriate management of each condition.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 02, 2021, through September 01, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert insights from ACR 2021, including the most important data to clinical practice on the management of axPsA and axSpA, from Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: December 23, 2021

Expert insights from ACR 2021, including the most important data for clinical practice on the management of axSpA and axPsA, from Clinical Care Options (CCO)

Atul Deodhar, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 22, 2021 Expired: December 21, 2022

Video from Clinical Care Options (CCO) featuring expert insights into the whole-patient approach including treatment selection, common comorbidities, and coordination of care for patients with PsO/PsA.

April W. Armstrong, MD, MPH Philip Mease, MD, MACR Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: August 27, 2021 Expired: August 26, 2022

Dr. Atul Deodhar discusses the latest clinically relevant data on drug-free remission in axSpA, MRI for axSpA diagnosis, vaccination for COVID-19 in patients with autoimmune inflammatory rheumatic diseases from Clinical Care Options (CCO).

Atul Deodhar, MD Released: August 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings